Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

  • In development
  • GID-TA11096
  • Expected publication date: TBC

 

 

 

Notice of Appeal 
 

Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

 

 

NICE have/has received 4 appeals, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations:

  • Muscular Dystrophy UK
  • Association of British Neurologists
  • UCB Pharma Limited
  • Myaware

 

The appeal panel will convene on Wednesday 19  November at 10:00am via Zoom to hear oral representations from the appellants.  

 

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.  

 

Where possible, requests to attend should be made using the registration link that will be available on our website from Monday 25 August 2025. The registration period for this appeal will end at 4:00pm on Wednesday 12 November.  

 

Further details relating to public attendance at this appeal are available on the same webpage as above. 

 

 

 

Documents